What does EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY do?

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is an events organiser in Brussel. Int. non-profit, started on 4 January 1988, 1 establishment.

What is the address of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

The registered office of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is located at Marnixlaan 17, 1000 Brussel.

Is EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY still active?

Yes. According to the CBE (27 September 2026) EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is active, legal situation “Normale toestand”, started on 4 January 1988.

Is EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY registered on Peppol?

Yes, EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is registered on the Peppol network with ID 0208:0432894370.

What is the enterprise number of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

The enterprise number of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is BE0432894370.

Who are the directors of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

According to the 2025 annual accounts, the directors of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY are: Hurkmans Coen, Luca Boldrini , MATTHIAS GUCKENBERGER , UULKE VAN DER HEIDE , Piet Ost, ANNA KIRBY, MARIANNE AZNAR , KARI TANDERUP.

Is EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 January 1988; 5 annual accounts filed, latest fiscal year 2025; 14 directors known from the annual account.

How much profit did EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY make in 2025?

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY posted a profit after taxes of € 235,055 in financial year 2025.

What is the revenue of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

As a small company, EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 3,652,955.

How much does an employee at EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY earn?

The average wage cost per full-time employee at EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY was € 110,600 in 2025: staff costs of € 3 million for 27 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY have?

According to the 2025 annual accounts, EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY has 27 full-time equivalents (FTE).

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY (Int. non-profit)

Q: When was EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY founded?

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY was founded on 4 January 1988.

Dossier EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY, printed on 27 September 2026 from databakkes.be/en/0432894370/european-society-for-radiotherapy-and-oncology. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

22 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY from Brussel, company number BE0432894370, closed financial year 2025 with a result of € 235,055 after tax. For that financial year EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY recorded a gross margin of € 3.7 million and equity of € 4.1 million. Compared with financial year 2024, the result moved from € 828,799 to € 235,055. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.

What it is worth Growing

€ 4.1 million

▲ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 235,055

▼ 72% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2.7 million

▼ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 3 million

▲ 7% vs 2024

€ 110,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 22,465

▲ 44% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1.1 million

▲ 38% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 618,918

▲ 21% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 3,092,839 Gross margin 2022: € 3,092,839 First fiscal year in the series	€ 3,204,218 Gross margin 2023: € 3,204,218 ▲ 4% vs 2022 (€ 3,092,839) Favourable step	€ 3,716,653 Gross margin 2024: € 3,716,653 ▲ 16% vs 2023 (€ 3,204,218) Favourable step	€ 3,652,955 Gross margin 2025: € 3,652,955 ▼ 2% vs 2024 (€ 3,716,653) Unfavourable step	▼ 2%
Profit after taxes	€ 468,412 Profit after taxes 2022: € 468,412 First fiscal year in the series	€ 628,362 Profit after taxes 2023: € 628,362 ▲ 34% vs 2022 (€ 468,412) Favourable step	€ 828,799 Profit after taxes 2024: € 828,799 ▲ 32% vs 2023 (€ 628,362) Favourable step	€ 235,055 Profit after taxes 2025: € 235,055 ▼ 72% vs 2024 (€ 828,799) Unfavourable step	▼ 72%
Equity	€ 2,431,759 Equity 2022: € 2,431,759 First fiscal year in the series	€ 3,060,121 Equity 2023: € 3,060,121 ▲ 26% vs 2022 (€ 2,431,759) Favourable step	€ 3,888,920 Equity 2024: € 3,888,920 ▲ 27% vs 2023 (€ 3,060,121) Favourable step	€ 4,123,975 Equity 2025: € 4,123,975 ▲ 6% vs 2024 (€ 3,888,920) Favourable step	▲ 6%
Total debts	€ 4,669,905 Total debts 2022: € 4,669,905 First fiscal year in the series	€ 4,341,699 Total debts 2023: € 4,341,699 ▼ 7% vs 2022 (€ 4,669,905) Favourable step	€ 5,143,649 Total debts 2024: € 5,143,649 ▲ 18% vs 2023 (€ 4,341,699) Unfavourable step	€ 5,934,605 Total debts 2025: € 5,934,605 ▲ 15% vs 2024 (€ 5,143,649) Unfavourable step	▲ 15%
Cash	€ 2,224,405 Cash 2022: € 2,224,405 First fiscal year in the series	€ 1,393,560 Cash 2023: € 1,393,560 ▼ 37% vs 2022 (€ 2,224,405) Unfavourable step	€ 3,394,363 Cash 2024: € 3,394,363 ▲ 144% vs 2023 (€ 1,393,560) Favourable step	€ 2,729,501 Cash 2025: € 2,729,501 ▼ 20% vs 2024 (€ 3,394,363) Unfavourable step	▼ 20%
Retained profit	€ 943,596 Retained profit 2022: € 943,596 First fiscal year in the series	€ 1,571,958 Retained profit 2023: € 1,571,958 ▲ 67% vs 2022 (€ 943,596) Favourable step	€ 2,400,758 Retained profit 2024: € 2,400,758 ▲ 53% vs 2023 (€ 1,571,958) Favourable step	€ 2,635,813 Retained profit 2025: € 2,635,813 ▲ 10% vs 2024 (€ 2,400,758) Favourable step	▲ 10%
Bank debt	€ 267,676 Bank debt 2022: € 267,676 First fiscal year in the series	€ 167,568 Bank debt 2023: € 167,568 ▼ 37% vs 2022 (€ 267,676) Favourable step	€ 67,137 Bank debt 2024: € 67,137 ▼ 60% vs 2023 (€ 167,568) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 67,137) Favourable step	▼ 100%
Balance sheet total	€ 7,101,664 Balance sheet total 2022: € 7,101,664 First fiscal year in the series	€ 7,401,820 Balance sheet total 2023: € 7,401,820 ▲ 4% vs 2022 (€ 7,101,664) Unchanged	€ 9,032,570 Balance sheet total 2024: € 9,032,570 ▲ 22% vs 2023 (€ 7,401,820) Unchanged	€ 10,058,580 Balance sheet total 2025: € 10,058,580 ▲ 11% vs 2024 (€ 9,032,570) Unchanged	▲ 11%
Employees (FTE)	26.3 Employees (FTE) 2022: 26.3 First fiscal year in the series	26.1 Employees (FTE) 2023: 26.1 ▼ 0.2 vs 2022 (26.3) Unchanged	26.4 Employees (FTE) 2024: 26.4 ▲ 0.3 vs 2023 (26.1) Unchanged	27 Employees (FTE) 2025: 27 ▲ 0.6 vs 2024 (26.4) Unchanged	▲ 0.6

Key figures of EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

What happened at EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Barbara Alicia Jereczek stepped down as director. NBB
2030 ESTHER G.C TROOST stepped down as director. NBB
2028 MATTHIAS GUCKENBERGER stepped down as director. NBB
2028 Hurkmans Coen stepped down as director. NBB
2028 Luca Boldrini stepped down as director. NBB
2028 KERSTIN BORGMANN stepped down as director. NBB
2028 Catharine Clark stepped down as director. NBB
2028 Piet Ost stepped down as director. NBB

In short

From € 468,412 profit in 2022 to € 235,055 profit in 2025.

Best year ever: 2024, with € 828,799 profit.

On average € 135,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY? We notify you, reason included.

Follow EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Directors

According to the 2025 annual accounts

Hurkmans Coen

Director

since 2025 · until 2028

Luca Boldrini

Director

since 2024 · until 2028

MATTHIAS GUCKENBERGER

Chairman of the board

since 2018 · until 2028

UULKE VAN DER HEIDE

Director

since 2023 · until 2027

Piet Ost

Director

Also active at: DR. PIET OST, RADIOTHERAPIE

since 2025 · until 2028

ANNA KIRBY

Director

since 2019 · until 2026

MARIANNE AZNAR

Director

since 2023 · until 2027

KARI TANDERUP

Director

since 2021 · until 2026

Barbara Alicia Jereczek

Director

since 2024 · until 2030

KERSTIN BORGMANN

Director

since 2022 · until 2028

Catharine Clark

Director

since 2023 · until 2028

Meattini Icro

Director

since 2023 · until 2026

ELISABETH FORDE

Director

since 2021 · until 2026

ESTHER G.C TROOST

Director

since 2021 · until 2030

Establishments

Establishment units

Physical locations of this company

Registered office

Marnixlaan 17

1000 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 22 companies are registered at this address.

All companies at this address →

The Fifth Avenue Antique Shop

SIX Financial Information Belgium

€ 9.2 million revenue · 2025

ICF NEXT

€ 48.3 million revenue · 2025

AKTOR KNOWLEDGE TECHNOLOGY

€ 7.4 million revenue · 2024

CONFEDERATION OF THE EUROPEAN BICYCLE INDUSTRY

+17 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0432.894.370
VAT number: BE 0432.894.370
Registered office: Marnixlaan 17, 1000 Brussel
Names & denominations: EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY · ESTRO
Enterprise type: Rechtspersoon
Legal form: International non-profit association
Legal situation: Normale toestand
Start date: 4 January 1988
Peppol: Active · Active since 1 Jan 2001
Activities · NACE: Organisatie van congressen en beurzen

View on CBE Public ↗ Annual accounts (NBB) ↗

EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY

Warning lights

Financials

What happened to EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions